PAA, A New Dawn , FDA ODD Approval and Entering Phase II MND Trial, page-874

Fingers crossed. I note MT made clear in comments recently that the aim is a transaction after the 24 week mark (interim). As opposed to waiting until 48 month mark and full approval. I found this interesting in the sense that it is a very clear plan on when they want to commercialise.

By this point we will have results from Alzheimer's etc testing, OLE data, initial framework for European regulatory entry and the all-important phase 2 data.

But think that a transaction is probably as likely to occur maybe mid-way through the trial once a few of those other items have been published (OLE x another 2 quarters of results, other neuro pre-clinical results), even in the absence of the final phase 2 outcome. $USD2 billion buyout mid 2025? Yes please...